12/3
06:31 pm
tcrx
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities [Yahoo! Finance]
Medium
Report
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities [Yahoo! Finance]
12/3
04:05 pm
tcrx
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
Medium
Report
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
11/14
10:53 am
tcrx
TScan Therapeutics (NASDAQ:TCRX) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.
Low
Report
TScan Therapeutics (NASDAQ:TCRX) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.
11/13
08:11 am
tcrx
TScan Therapeutics (NASDAQ:TCRX) had its price target lowered by analysts at HC Wainwright from $10.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
TScan Therapeutics (NASDAQ:TCRX) had its price target lowered by analysts at HC Wainwright from $10.00 to $7.00. They now have a "buy" rating on the stock.
11/12
07:00 am
tcrx
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/5
07:00 am
tcrx
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Low
Report
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
11/4
08:09 am
tcrx
TScan Therapeutics (NASDAQ:TCRX) had its price target lowered by analysts at Needham & Company LLC from $9.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
TScan Therapeutics (NASDAQ:TCRX) had its price target lowered by analysts at Needham & Company LLC from $9.00 to $6.00. They now have a "buy" rating on the stock.
11/4
07:03 am
tcrx
TScan Therapeutics (NASDAQ:TCRX) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.
Medium
Report
TScan Therapeutics (NASDAQ:TCRX) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.
11/3
06:30 am
tcrx
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
High
Report
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
10/25
12:13 pm
tcrx
TScan Therapeutics (NASDAQ:TCRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TScan Therapeutics (NASDAQ:TCRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/17
07:00 am
tcrx
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
Medium
Report
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025